本帖最后由 maicon08 于 2023-4-28 15:12 编辑
) m4 V( ^) S' h6 n# d4 S9 f& z, d
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。
" S+ z7 q _$ J2 s! [- z. b4 }% K# _; Q' p. U% m- I
https://www.163.com/dy/article/I3BTTPRD053438SI.html
; @ O7 q5 J$ E* D- A; u/ x$ \
9 S( O+ i( X( w: k+ ]+ i* D
6 p+ f8 ]/ Q; C {, W: p* d在研疗法-免疫治疗
# |& t/ D8 T; J) uDevelopmental Therapeutics—Immunotherapy8 c. f) r# w) `, Z7 s
' R1 i) \) T" t
摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心 8 F5 ]8 m# ?/ [9 A" s: d
在研疗法-分子靶向药物和肿瘤生物学
3 T+ h- A2 g$ r/ B# ` u* p5 o Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology 5 E6 L$ ^0 @* S) g! R( V2 \/ q
摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
, }* h/ ~/ M) h
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 5 _4 @4 e o7 D9 F# _5 u
胃肠道肿瘤-结直肠癌和肛门癌
" a) K2 ^ N$ q Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 % G. } \4 Y' i% E% P j1 {
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary + e7 E2 e* _& g5 l b
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心 7 h) |8 B4 [$ O) `: G/ @% m
妇科肿瘤 Gynecologic Cancer
% y- u% k3 X" ^; U* {$ S( b8 _6 Y摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院
; ~3 q+ X9 X0 i# ~. }
头颈肿瘤; g6 z2 n$ U7 _. ^' z7 |; o
Head and Neck Cancer 8 H2 ~2 P0 h. H1 e
摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心 - z1 S( A( j! p9 \; C2 W! y
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心 . P Z1 f ^: c+ L; A
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 - n0 a9 e% h; |& @$ r
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
* E9 X6 t4 r6 P, G* M4 g0 }* L摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心 & \7 ]" x% d2 C
血液系统恶性肿瘤-浆细胞疾病
0 E" S+ ^' M7 @* W) W Hematologic Malignancies—Plasma Cell Dyscrasia 3 o% G, k8 q7 H. W2 R* o0 p e4 I; r! \
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院 6 F9 {8 @/ E7 C5 f9 U% S+ e. m
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤1 K! f* |3 n3 P% \& E* ~+ R
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
0 v- l! r* k: @摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院
4 t, Y4 q9 E; I
肺癌-转移性非小细胞肺癌
[. t+ @$ Z8 `" y Lung Cancer—Non-Small Cell Metastatic
) x, P( @$ d% S0 o摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院 : {, Q' i' ^3 q4 `& a
3 {; K+ R, M$ X9 p1 M/ U
摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
% L' M) c+ w4 t, Z
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院 9 N" c# Y! ^1 q- R( e
黑色素瘤/皮肤癌
' K. M- B) a# H# U Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院
6 S2 G# e! f% }! L, u
快速摘要报告
. d; m1 z* {9 ^: F1 n Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
O7 G9 q% X, \# e
临床科学研讨会
3 g# W- G) W" s- v7 o; |& y8 m Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院
2 `5 r4 w* r! X6 d# i! i3 `$ |3 }- W' C) I( K9 t' q3 S2 Q5 c$ e
| 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
